Madison M. Lenormand
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Madison M. Lenormand has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Aditi Gulati
10The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom
11 shared publications - Anastasia Loktev
11Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom
11 shared publications - Antonio Romo-Morales
11Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom
11 shared publications - Astrid Zimmermann
Translational Innovation Platform Oncology and Immuno-Oncology, The Healthcare Business of Merck KGaA, Darmstadt, Germany
11 shared publications - Asuka Kawai-Kawachi
Division of Cancer RNA Research, National Cancer Center Research Institute, Chuo-ku, Japan
11 shared publications - Axel Le Cesne
Gustave Roussy, Villejuif, France
11 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors
Supplementary File containing methods, figures and uncropped membranes.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors
Supplementary File containing methods, figures and uncropped membranes.
- 9 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Investigating checkpoint response dynamics during double-strand break repair at single-cell resolution
Étude de la dynamique de réponse des points de contrôle lors de la réparation des cassures double brin à une résolution de cellule unique: La tumorigenèse résulte principalement de l'instabilité génomique causée par des réparations aberrantes des dommages à l'ADN, notamment les cassures double brin (DSB). Ces dernières proviennent de menaces métaboliques et externes, comme les erreurs de réplication, les cassures simple brin (SSB) ou les radiations ionisantes. Une fois détectées, elles sont réparées via la voie DSBR après reconnaissance par les protéines de point de contrôle et via la régulation du cycle cellulaire. Rad53 est une kinase clé de la signalisation DSBR, arrêtant les cellules en G2/M pour permettre la réparation avant la mitose. Une dérégulation du point de contrôle permet aux cellules endommagées d'échapper à l'arrêt du cycle, favorisant la néoplasie. Si cette voie a été étudiée à l'échelle de populations, sa dynamique au niveau cellulaire individuel reste peu explorée. J'ai construit des souches de Saccharomyces cerevisiae portant deux rapporteurs fluorescents pour analyser la réponse aux DSB : un système GFP bipartite où une DSB induite par CRISPR génère des cellules GFP+ après recombinaison réussie, et un rapporteur Rad53-mCherry qui s'accumule dans le noyau lors de l'activation du point de contrôle. Les séquences répétées étant associées à une réparation plus erronée et à une croissance altérée, j'ai conçu des souches avec des répétitions trinucleotidiques (CTG et GAA) au site cible GFP, ainsi qu'une souche sans répétition (NR) pour mieux comprendre l'impact de ces répétitions sur la réponse au point de contrôle. J'ai utilisé une puce microfluidique pour suivre la réponse du point de contrôle à l'échelle de la cellule unique, en analysant l'intensité nucléaire de Rad53 au cours de la division et de la réparation. J'ai développé un pipeline expérimental combinant une puce microfluidique imprimée en 3D et de la microscopie confocale en time-lapse. Une analyse d'image semi-automatisée avancée a permis d'extraire des informations quantitatives sur la division cellulaire, la taille, la trajectoire, la réparation et la réponse au point de contrôle. Cette approche m'a permis de suivre la progression des lignées cellulaires et l'apparition de GFP comme marqueur de la réparation, en lien avec la localisation nucléaire de Rad53-mCherry au fil du temps. J'ai étudié l'influence des nucléases et des séquences cibles sur la réponse au point de contrôle en présence et en absence de DSB ciblées. Dans les cellules NR sans DSB exogène, Rad53 se localise dans le noyau en phase S, en corrélation avec la division. Après induction de DSB par des nucléases, la souche NR a montré des réponses distinctes : Cas9 et Cpf1 ont induit une réparation efficace mais des signatures Rad53 différentes, tandis que I-SceI n'a pas induit efficacement de DSB, générant un comportement similaire aux cellules non endommagées. En revanche, les cellules avec séquences répétées ont présenté une accumulation prolongée de Rad53 dans le noyau et une morphologie altérée après une DSB induite par Cas9. Ce type de comportement n'est pas induit par Cpf1, qui a généré une réparation différente. De plus, un mutant rad52 a présenté un profil unique d'adaptation, avec une accumulation de Rad53 sur deux phases distinctes, traduisant des tentatives de réparation échouées et un ralentissement de la division. Ce projet propose une approche inédite pour étudier la dynamique du point de contrôle et la réparation à l'échelle cellulaire unique en utilisant la microscopie en time-lapse. Il a révélé que la dynamique de Rad53 dépend des événements de division et de réparation, et que la réponse au point de contrôle varie selon la nucléase et la séquence cible. Ce travail ouvre la voie à de futures études sur la réparation de l'ADN et l'utilisation des technologies microfluidiques pour quantifier ces processus.
- 9 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Investigating checkpoint response dynamics during double-strand break repair at single-cell resolution
Étude de la dynamique de réponse des points de contrôle lors de la réparation des cassures double brin à une résolution de cellule unique: La tumorigenèse résulte principalement de l'instabilité génomique causée par des réparations aberrantes des dommages à l'ADN, notamment les cassures double brin (DSB). Ces dernières proviennent de menaces métaboliques et externes, comme les erreurs de réplication, les cassures simple brin (SSB) ou les radiations ionisantes. Une fois détectées, elles sont réparées via la voie DSBR après reconnaissance par les protéines de point de contrôle et via la régulation du cycle cellulaire. Rad53 est une kinase clé de la signalisation DSBR, arrêtant les cellules en G2/M pour permettre la réparation avant la mitose. Une dérégulation du point de contrôle permet aux cellules endommagées d'échapper à l'arrêt du cycle, favorisant la néoplasie. Si cette voie a été étudiée à l'échelle de populations, sa dynamique au niveau cellulaire individuel reste peu explorée. J'ai construit des souches de Saccharomyces cerevisiae portant deux rapporteurs fluorescents pour analyser la réponse aux DSB : un système GFP bipartite où une DSB induite par CRISPR génère des cellules GFP+ après recombinaison réussie, et un rapporteur Rad53-mCherry qui s'accumule dans le noyau lors de l'activation du point de contrôle. Les séquences répétées étant associées à une réparation plus erronée et à une croissance altérée, j'ai conçu des souches avec des répétitions trinucleotidiques (CTG et GAA) au site cible GFP, ainsi qu'une souche sans répétition (NR) pour mieux comprendre l'impact de ces répétitions sur la réponse au point de contrôle. J'ai utilisé une puce microfluidique pour suivre la réponse du point de contrôle à l'échelle de la cellule unique, en analysant l'intensité nucléaire de Rad53 au cours de la division et de la réparation. J'ai développé un pipeline expérimental combinant une puce microfluidique imprimée en 3D et de la microscopie confocale en time-lapse. Une analyse d'image semi-automatisée avancée a permis d'extraire des informations quantitatives sur la division cellulaire, la taille, la trajectoire, la réparation et la réponse au point de contrôle. Cette approche m'a permis de suivre la progression des lignées cellulaires et l'apparition de GFP comme marqueur de la réparation, en lien avec la localisation nucléaire de Rad53-mCherry au fil du temps. J'ai étudié l'influence des nucléases et des séquences cibles sur la réponse au point de contrôle en présence et en absence de DSB ciblées. Dans les cellules NR sans DSB exogène, Rad53 se localise dans le noyau en phase S, en corrélation avec la division. Après induction de DSB par des nucléases, la souche NR a montré des réponses distinctes : Cas9 et Cpf1 ont induit une réparation efficace mais des signatures Rad53 différentes, tandis que I-SceI n'a pas induit efficacement de DSB, générant un comportement similaire aux cellules non endommagées. En revanche, les cellules avec séquences répétées ont présenté une accumulation prolongée de Rad53 dans le noyau et une morphologie altérée après une DSB induite par Cas9. Ce type de comportement n'est pas induit par Cpf1, qui a généré une réparation différente. De plus, un mutant rad52 a présenté un profil unique d'adaptation, avec une accumulation de Rad53 sur deux phases distinctes, traduisant des tentatives de réparation échouées et un ralentissement de la division. Ce projet propose une approche inédite pour étudier la dynamique du point de contrôle et la réparation à l'échelle cellulaire unique en utilisant la microscopie en time-lapse. Il a révélé que la dynamique de Rad53 dépend des événements de division et de réparation, et que la réponse au point de contrôle varie selon la nucléase et la séquence cible. Ce travail ouvre la voie à de futures études sur la réparation de l'ADN et l'utilisation des technologies microfluidiques pour quantifier ces processus.
- Open Access
- 2 January 2025
- Published by American Association for Cancer Research (AACR)
Figure 4 from Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors
EWS–WT1 is a determinant of DSRCT cells’ sensitivity to PARPi and ATRi. A, Western blot of EWS–WT1 in JN1 and R cells transfected with either siCNTRL or siEWS–WT1. Whole-cell lysates were generated 48 hours after transfection. B–E, Dose–response survival curves of JN1 or R cells exposed to PARPi talazoparib (B and C) or ATRi M4344 (D and E) for 7 days in the presence or absence of siRNA-mediated silencing of EWS–WT1. Mean ± SD; n = 3. F and G, Quantification of γH2AX in JN1 cells exposed to DMSO control, PARPi talazoparib, ATRi M4344, or a combination of both for 72 hours, in the presence or absence of siRNA-mediated silencing of EWS–WT1. Cisplatin was used as the positive control. A minimum of 500 nuclei was analyzed per condition. Violin plots show the absolute number of foci per nucleus. Thick line, median; thin lines, bottom and top quartiles; two-way ANOVA and post hoc Dunn test. H and I, Western blots of pCHK1, CHK1, pRPA2, RPA2, γH2AX, H2AX, and EWS–WT1 in JN1 (H) or R (I) cells exposed to DMSO control, PARPi talazoparib (Tala), ATRi M4344, or a combination of both for 48 hours, in the presence or absence of siRNA-mediated silencing of EWS–WT1. ****, P < 0.0001; ns, not significant.
- 2 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors
EWS–WT1 is a determinant of DSRCT cells’ sensitivity to PARPi and ATRi. A, Western blot of EWS–WT1 in JN1 and R cells transfected with either siCNTRL or siEWS–WT1. Whole-cell lysates were generated 48 hours after transfection. B–E, Dose–response survival curves of JN1 or R cells exposed to PARPi talazoparib (B and C) or ATRi M4344 (D and E) for 7 days in the presence or absence of siRNA-mediated silencing of EWS–WT1. Mean ± SD; n = 3. F and G, Quantification of γH2AX in JN1 cells exposed to DMSO control, PARPi talazoparib, ATRi M4344, or a combination of both for 72 hours, in the presence or absence of siRNA-mediated silencing of EWS–WT1. Cisplatin was used as the positive control. A minimum of 500 nuclei was analyzed per condition. Violin plots show the absolute number of foci per nucleus. Thick line, median; thin lines, bottom and top quartiles; two-way ANOVA and post hoc Dunn test. H and I, Western blots of pCHK1, CHK1, pRPA2, RPA2, γH2AX, H2AX, and EWS–WT1 in JN1 (H) or R (I) cells exposed to DMSO control, PARPi talazoparib (Tala), ATRi M4344, or a combination of both for 48 hours, in the presence or absence of siRNA-mediated silencing of EWS–WT1. ****, P < 0.0001; ns, not significant.
- Open Access
- 2 January 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors
A small-molecule inhibitor and drug screen identifies PARPi and ATRi as candidate therapies for DSRCT. A, Schematic illustration of the workflow of small-molecule inhibitor and drug screen performed on the JN1 cell line. B, Waterfall plot displaying the difference in AUC between the JN1 cell line (AUCJN1) and the panel of 92 cell lines used for comparison (AUCmedian) for the 79 evaluated small-molecule inhibitors or drugs. Red, PARPi; blue, ATRi; green, conventional cytotoxic. C–F, Dose–response survival curves of the DSRCT cell lines JN1 and R, and the A673 (Ewing sarcoma) and SaOS-2 (osteosarcoma) cell lines exposed to talazoparib (C), olaparib (D), M4344 (E), or AZD6738 (F) for 7 days. Mean ± SD; n = 3. G and H, Violin plots showing the relative sensitivity (log2-fold change of cell viability) of cell lines exposed to the PARPi talazoparib (G) or olaparib (H) after a single-dose exposure at 2.5 μmol/L for 5 days in the DepMap database (PRISM Repurposing 23Q2), in comparison with that of the JN1 and R cell lines. JN1 and R cell line sensitivities were extrapolated from the survival assays presented in C and E; SFs were calculated at 2.5 μmol/L and log2 transformed. Ewing sarcoma cell lines (n = 16): RDES, A673, SKES1, CADOES1, EWS502, MHHES1, EW8, A673STAG2KO16, A673STAG2KO45, A673STAG2NT14, A673STAG2NT23, CBAGPN, CHLA10, SKNEP1, SKPNDW, and TC32; osteosarcoma cell lines (n = 5): G292CLONEA141B1, MG63, U2OS, HOS, and SJSA1; soft-tissue sarcoma cell lines (n = 7): S117, TE617T, HT1080, HS729, RD, RKN, and RH30, including rhabdomyosarcoma (n = 4), leiomyosarcoma (n = 1), fibrosarcoma (n = 1), and NOS sarcoma cell lines (n = 1), respectively. The BRCA1/2-mutant IGROV1 ovarian cancer cell line and BRCA1-mutant MDA-MB-436 breast cancer cell line were used as positive controls for sensitivity to PARPi. **, P < 0.01; ****, P < 0.0001; ns, not significant.
- 2 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors
A small-molecule inhibitor and drug screen identifies PARPi and ATRi as candidate therapies for DSRCT. A, Schematic illustration of the workflow of small-molecule inhibitor and drug screen performed on the JN1 cell line. B, Waterfall plot displaying the difference in AUC between the JN1 cell line (AUCJN1) and the panel of 92 cell lines used for comparison (AUCmedian) for the 79 evaluated small-molecule inhibitors or drugs. Red, PARPi; blue, ATRi; green, conventional cytotoxic. C–F, Dose–response survival curves of the DSRCT cell lines JN1 and R, and the A673 (Ewing sarcoma) and SaOS-2 (osteosarcoma) cell lines exposed to talazoparib (C), olaparib (D), M4344 (E), or AZD6738 (F) for 7 days. Mean ± SD; n = 3. G and H, Violin plots showing the relative sensitivity (log2-fold change of cell viability) of cell lines exposed to the PARPi talazoparib (G) or olaparib (H) after a single-dose exposure at 2.5 μmol/L for 5 days in the DepMap database (PRISM Repurposing 23Q2), in comparison with that of the JN1 and R cell lines. JN1 and R cell line sensitivities were extrapolated from the survival assays presented in C and E; SFs were calculated at 2.5 μmol/L and log2 transformed. Ewing sarcoma cell lines (n = 16): RDES, A673, SKES1, CADOES1, EWS502, MHHES1, EW8, A673STAG2KO16, A673STAG2KO45, A673STAG2NT14, A673STAG2NT23, CBAGPN, CHLA10, SKNEP1, SKPNDW, and TC32; osteosarcoma cell lines (n = 5): G292CLONEA141B1, MG63, U2OS, HOS, and SJSA1; soft-tissue sarcoma cell lines (n = 7): S117, TE617T, HT1080, HS729, RD, RKN, and RH30, including rhabdomyosarcoma (n = 4), leiomyosarcoma (n = 1), fibrosarcoma (n = 1), and NOS sarcoma cell lines (n = 1), respectively. The BRCA1/2-mutant IGROV1 ovarian cancer cell line and BRCA1-mutant MDA-MB-436 breast cancer cell line were used as positive controls for sensitivity to PARPi. **, P < 0.01; ****, P < 0.0001; ns, not significant.
- Open Access
- 2 January 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors
PARPi and ATRi have synergistic cytotoxic effects in models of DSRCT with high PARP1 expression. A and B, PARP1 expression (A) and PARylation levels (B) as assessed by IHC in a cohort of 16 DSRCT samples, compared with those of the JN1 and R cell lines (PARP1 and PAR expression levels are shown as H-scores). Representative cases (PARP1-high vs. PARP1-low tumors; PAR-high vs. PAR-low tumors) are shown to the right, compared with JN1 and R cells. C and D, Surface plots of Bliss independence scores calculated for the talazoparib–M4344 combination in JN1 (C) and R (D) cell lines at 7 days. E, The GR_13-PDX-O model was established from the primary peritoneal tumor of a patient with DSRCT, with confirmation of EWSR1::WT1 fusion by FISH and WT1-Cter IHC (Supplementary Fig. S8). F, Surface plot of Bliss independence scores calculated for the talazoparib–M4344 combination in the GR_13 PDX-O at 7 days. Mean ± SD; n = 3. Surface plots: the x-axis and y-axis values indicate drug concentrations, and the z-axis values indicate the associated synergy score; score < −10, antagonistic interaction; score = 0, absence of interaction; score > 10, synergistic interaction. G, Schematic illustration of an in vivo therapeutic experiment performed to evaluate the antitumor effect of PARPi talazoparib and ATRi M1774 in NSG mice engrafted with JN1 xenografts. H, Therapeutic responses to drug treatment in mice harboring JN1 xenografts. Mean tumor volume ± SD; two-way ANOVA and post hoc Dunnett test. I, Tumor volume at the time of mice sacrifice. Mean ± SD; one-way ANOVA and post hoc Šídák test. *, P < 0.01; ns, not significant. Tala, talazoparib.
- 2 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors
PARPi and ATRi have synergistic cytotoxic effects in models of DSRCT with high PARP1 expression. A and B, PARP1 expression (A) and PARylation levels (B) as assessed by IHC in a cohort of 16 DSRCT samples, compared with those of the JN1 and R cell lines (PARP1 and PAR expression levels are shown as H-scores). Representative cases (PARP1-high vs. PARP1-low tumors; PAR-high vs. PAR-low tumors) are shown to the right, compared with JN1 and R cells. C and D, Surface plots of Bliss independence scores calculated for the talazoparib–M4344 combination in JN1 (C) and R (D) cell lines at 7 days. E, The GR_13-PDX-O model was established from the primary peritoneal tumor of a patient with DSRCT, with confirmation of EWSR1::WT1 fusion by FISH and WT1-Cter IHC (Supplementary Fig. S8). F, Surface plot of Bliss independence scores calculated for the talazoparib–M4344 combination in the GR_13 PDX-O at 7 days. Mean ± SD; n = 3. Surface plots: the x-axis and y-axis values indicate drug concentrations, and the z-axis values indicate the associated synergy score; score < −10, antagonistic interaction; score = 0, absence of interaction; score > 10, synergistic interaction. G, Schematic illustration of an in vivo therapeutic experiment performed to evaluate the antitumor effect of PARPi talazoparib and ATRi M1774 in NSG mice engrafted with JN1 xenografts. H, Therapeutic responses to drug treatment in mice harboring JN1 xenografts. Mean tumor volume ± SD; two-way ANOVA and post hoc Dunnett test. I, Tumor volume at the time of mice sacrifice. Mean ± SD; one-way ANOVA and post hoc Šídák test. *, P < 0.01; ns, not significant. Tala, talazoparib.
- Open Access
- 2 January 2025
- Published by American Association for Cancer Research (AACR)
Figure 5 from Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors
EWS–WT1 drives enhanced DNA replication stress and R-loops, which contribute to DSRCT cells’ sensitivity to PARPi and ATRi. A, Assessment of replication fork speed (kb/minute) in JN1 cells subjected to siRNA-mediated silencing of EWS–WT1 or CCND1. A minimum of 50 forks was analyzed per condition. Mean ± SD; each dot represents a single replication fork; n = 2, one-way ANOVA and post hoc Dunnett test. B, Assessment of replication fork speed (kb/minute) in JN1 cells exposed to DMSO control, or a combination of PARPi talazoparib (Tala) and ATRi M4344 for 6 hours, in the presence or absence of siRNA-mediated silencing of EWS–WT1. A minimum of 50 forks was analyzed per condition. Mean ± SD; each dot represents a single replication fork; n = 2; two-way ANOVA and post hoc Šídák test. C and D, DNA:RNA hybrid dot blot of genomic DNA extracted from JN1 (C) or R (D) cells exposed to PARPi talazoparib, ATRi M4344, or a combination of both in the presence or absence of siRNA-mediated silencing of EWS–WT1 as in B. S9.6, RNA:DNA hybrids; ssDNA, loading control. E, Assessment of replication fork speed (kb/minute) in RNase H1–overexpressing JN1 cells subjected to siRNA-mediated silencing of EWS–WT1. Synchronized cells were collected 14 hours after transfection. A minimum of 50 forks was analyzed per condition. Mean ± SD; each dot represents a single replication fork; n = 2; unpaired t test. E, Dose–response survival curves of JN1 cells exposed to PARPi talazoparib (F) or olaparib (G), and ATRi M4344 (H) or AZD6738 (I) for 7 days in the presence or absence of siRNA-mediated silencing of EWS–WT1 and/or RNase H1 overexpression. Mean ± SD; n = 3; two-way ANOVA. *, P < 0.05; ****, P < 0.0001; ns, not significant.
- 2 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors
EWS–WT1 drives enhanced DNA replication stress and R-loops, which contribute to DSRCT cells’ sensitivity to PARPi and ATRi. A, Assessment of replication fork speed (kb/minute) in JN1 cells subjected to siRNA-mediated silencing of EWS–WT1 or CCND1. A minimum of 50 forks was analyzed per condition. Mean ± SD; each dot represents a single replication fork; n = 2, one-way ANOVA and post hoc Dunnett test. B, Assessment of replication fork speed (kb/minute) in JN1 cells exposed to DMSO control, or a combination of PARPi talazoparib (Tala) and ATRi M4344 for 6 hours, in the presence or absence of siRNA-mediated silencing of EWS–WT1. A minimum of 50 forks was analyzed per condition. Mean ± SD; each dot represents a single replication fork; n = 2; two-way ANOVA and post hoc Šídák test. C and D, DNA:RNA hybrid dot blot of genomic DNA extracted from JN1 (C) or R (D) cells exposed to PARPi talazoparib, ATRi M4344, or a combination of both in the presence or absence of siRNA-mediated silencing of EWS–WT1 as in B. S9.6, RNA:DNA hybrids; ssDNA, loading control. E, Assessment of replication fork speed (kb/minute) in RNase H1–overexpressing JN1 cells subjected to siRNA-mediated silencing of EWS–WT1. Synchronized cells were collected 14 hours after transfection. A minimum of 50 forks was analyzed per condition. Mean ± SD; each dot represents a single replication fork; n = 2; unpaired t test. E, Dose–response survival curves of JN1 cells exposed to PARPi talazoparib (F) or olaparib (G), and ATRi M4344 (H) or AZD6738 (I) for 7 days in the presence or absence of siRNA-mediated silencing of EWS–WT1 and/or RNase H1 overexpression. Mean ± SD; n = 3; two-way ANOVA. *, P < 0.05; ****, P < 0.0001; ns, not significant.
- Open Access
- 2 January 2025
- Published by American Association for Cancer Research (AACR)
Figure 6 from Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors
The combination of PARPi and ATRi elicits a cGAS–STING–mediated cell-autonomous immune response. A, Western blots of pTBK1, TBK, pIRF3, and IRF3 in JN1 cells exposed to DMSO control, PARPi talazoparib (Tala), ATRi M4344, or a combination of both for 72 hours. B and C, RT-qPCR analysis of RNA isolated from JN1 cells exposed to DMSO control, PARPi talazoparib, ATRi M4344, or a combination of both for 72 hours. CCL5 (B) and CXCL10 (C) mRNA were analyzed separately relative to RPLP0. Box and whisker plots show arbitrary units of gene expression, normalized to the DMSO condition. Boxes, median and lower and upper quartiles; whiskers, the 5th to 95th percentile range; n = 4; two-way ANOVA and post hoc Dunnett test, relative to the DMSO condition. D, Quantification of PD-L1 cell-surface expression by flow cytometry in JN1 cells exposed to DMSO control, PARPi talazoparib, ATRi M4344, or a combination of both for 72 hours. Scatter plot shows the percentage of PD-L1–positive cells within the DAPI-negative population, normalized to the DMSO condition. Mean ± SD; n = 3. Kruskal–Wallis test and post hoc Dunnett test, relative to the DMSO condition. E, Western blots of pTBK1, TBK, pIRF3, and IRF3 in JN1 cells exposed to DMSO control, PARPi talazoparib, ATRi M4344, or a combination of both for 72 hours, in the presence or absence of siRNA-mediated silencing of EWS–WT1. Appropriate silencing of EWS–WT1 was verified as shown in Fig. 4H. F and G, RT-qPCR analysis of RNA isolated from JN1 cells exposed to DMSO control, PARPi talazoparib, ATRi M4344, or a combination of both for 72 hours, in the presence or absence of siRNA-mediated silencing of EWS–WT1. CCL5 (F) and CXCL10 (G) mRNA were analyzed separately relative to RPLP0. Box and whisker plots show arbitrary units of gene expression, normalized to the siCNTRL DMSO condition. Boxes, median and lower and upper quartiles; whiskers, the 5th to 95th percentile range; n = 4; two-way ANOVA and post hoc Dunnett test, relative to the siCNTRL DMSO condition. H, Quantification of PD-L1 cell-surface expression by flow cytometry in JN1 cells exposed to DMSO control, PARPi talazoparib, ATRi M4344, or a combination of both for 72 hours, in the presence or absence of siRNA-mediated silencing of EWS–WT1. Scatter plot shows the percentage of PD-L1–positive cells within the DAPI-negative population, normalized to the siCNTRL DMSO condition. Mean ± SD; n = 3. Kruskal–Wallis test and post hoc Dunnett test, relative to the siCNTRL DMSO condition. I, Model of EWS–WT1–driven DSRCT sensitivity to PARPi and ATRi. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not significant. ISG, IFN-stimulated genes.
- 2 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 6 from Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors
The combination of PARPi and ATRi elicits a cGAS–STING–mediated cell-autonomous immune response. A, Western blots of pTBK1, TBK, pIRF3, and IRF3 in JN1 cells exposed to DMSO control, PARPi talazoparib (Tala), ATRi M4344, or a combination of both for 72 hours. B and C, RT-qPCR analysis of RNA isolated from JN1 cells exposed to DMSO control, PARPi talazoparib, ATRi M4344, or a combination of both for 72 hours. CCL5 (B) and CXCL10 (C) mRNA were analyzed separately relative to RPLP0. Box and whisker plots show arbitrary units of gene expression, normalized to the DMSO condition. Boxes, median and lower and upper quartiles; whiskers, the 5th to 95th percentile range; n = 4; two-way ANOVA and post hoc Dunnett test, relative to the DMSO condition. D, Quantification of PD-L1 cell-surface expression by flow cytometry in JN1 cells exposed to DMSO control, PARPi talazoparib, ATRi M4344, or a combination of both for 72 hours. Scatter plot shows the percentage of PD-L1–positive cells within the DAPI-negative population, normalized to the DMSO condition. Mean ± SD; n = 3. Kruskal–Wallis test and post hoc Dunnett test, relative to the DMSO condition. E, Western blots of pTBK1, TBK, pIRF3, and IRF3 in JN1 cells exposed to DMSO control, PARPi talazoparib, ATRi M4344, or a combination of both for 72 hours, in the presence or absence of siRNA-mediated silencing of EWS–WT1. Appropriate silencing of EWS–WT1 was verified as shown in Fig. 4H. F and G, RT-qPCR analysis of RNA isolated from JN1 cells exposed to DMSO control, PARPi talazoparib, ATRi M4344, or a combination of both for 72 hours, in the presence or absence of siRNA-mediated silencing of EWS–WT1. CCL5 (F) and CXCL10 (G) mRNA were analyzed separately relative to RPLP0. Box and whisker plots show arbitrary units of gene expression, normalized to the siCNTRL DMSO condition. Boxes, median and lower and upper quartiles; whiskers, the 5th to 95th percentile range; n = 4; two-way ANOVA and post hoc Dunnett test, relative to the siCNTRL DMSO condition. H, Quantification of PD-L1 cell-surface expression by flow cytometry in JN1 cells exposed to DMSO control, PARPi talazoparib, ATRi M4344, or a combination of both for 72 hours, in the presence or absence of siRNA-mediated silencing of EWS–WT1. Scatter plot shows the percentage of PD-L1–positive cells within the DAPI-negative population, normalized to the siCNTRL DMSO condition. Mean ± SD; n = 3. Kruskal–Wallis test and post hoc Dunnett test, relative to the siCNTRL DMSO condition. I, Model of EWS–WT1–driven DSRCT sensitivity to PARPi and ATRi. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not significant. ISG, IFN-stimulated genes.
- Open Access
- 2 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors
Supplementary File containing methods, figures and uncropped membranes.
- 2 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors
Supplementary File containing methods, figures and uncropped membranes.
- Open Access
- 2 January 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors
PARPi and ATRi combination elicits DNA damage, replication stress, and genomic instability in DSRCT cells. A–D, Quantification of γH2AX (A and B) or RAD51 foci (C and D) in JN1 (A and C) or R (B and D) cells exposed to DMSO control, PARPi talazoparib (Tala), ATRi M4344, or a combination of both for 72 hours. Cisplatin was used as the positive control. A minimum of 500 nuclei was analyzed per condition. Violin plots show the absolute number of foci per nucleus. Thick line, median; thin lines, bottom and top quartiles; two-way ANOVA and post hoc Dunn test. E and F, Western blots of pCHK1, CHK1, pRPA2, RPA2, γH2AX, H2AX, and cleaved-PARP1 (cPARP) in JN1 (E) or R (F) cells exposed to DMSO control, PARPi talazoparib or olaparib, ATRi M4344 or AZD6738, or a combination of both for 48 hours. G and H, Representative immunofluorescence images (G) and quantification (H) of micronuclei-positive cells in JN1 cells exposed to DMSO control, PARPi talazoparib, ATRi M4344, or a combination of both for 72 hours. A minimum of 500 cells was analyzed per condition. Mean ± SD; n = 3; one-way ANOVA and post hoc Dunn test. Arrows, micronuclei. Scale bar, 20 μm. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not significant.
- 2 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors
PARPi and ATRi combination elicits DNA damage, replication stress, and genomic instability in DSRCT cells. A–D, Quantification of γH2AX (A and B) or RAD51 foci (C and D) in JN1 (A and C) or R (B and D) cells exposed to DMSO control, PARPi talazoparib (Tala), ATRi M4344, or a combination of both for 72 hours. Cisplatin was used as the positive control. A minimum of 500 nuclei was analyzed per condition. Violin plots show the absolute number of foci per nucleus. Thick line, median; thin lines, bottom and top quartiles; two-way ANOVA and post hoc Dunn test. E and F, Western blots of pCHK1, CHK1, pRPA2, RPA2, γH2AX, H2AX, and cleaved-PARP1 (cPARP) in JN1 (E) or R (F) cells exposed to DMSO control, PARPi talazoparib or olaparib, ATRi M4344 or AZD6738, or a combination of both for 48 hours. G and H, Representative immunofluorescence images (G) and quantification (H) of micronuclei-positive cells in JN1 cells exposed to DMSO control, PARPi talazoparib, ATRi M4344, or a combination of both for 72 hours. A minimum of 500 cells was analyzed per condition. Mean ± SD; n = 3; one-way ANOVA and post hoc Dunn test. Arrows, micronuclei. Scale bar, 20 μm. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not significant.